Skip to content

OrthoPediatrics KIDS Debt - Unamortized Discount (Premium) and Issuance Costs, Net

Debt - Unamortized Discount (Premium) and Issuance Costs, Net at other companies

SI-BONE, Inc. logo
SI-BONE, Inc.SIBN
$401K-22.7%
Bioventus logo
BioventusBVS
$539K-45.6%
Enovis logo
EnovisENOV
$5.3M+65.6%
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
$9.5M-29.1%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$1.79M
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$59.4M+13.3%
Gross profit$43.4M+13.4%
Operating income-$8.3M+24.1%
Net income-$10.7M-0.3%
EPS (diluted)-$0.45+2.2%

Balance sheet

See full
Cash & equivalents$14.2M-59.8%
Total debt$5.4M+271%
Total equity$338.7M-2.4%
Total assets$502.2M+6.8%

Cash flow

See full
Operating cash flow-$3.3M+20.9%
CapEx$1.8M-58.4%
Free cash flow-$5.0M+39.8%

Valuation

See full
Market cap$503.94M+0.3%
Enterprise value$495.11M+5.7%
P/S2.1×-0.3×

Profitability

See full
Gross margin73.1%+0.3pp
Operating margin-15%-1.6pp
Net margin-16.3%-2.1pp
FCF margin-12.9%-4.3pp

Returns & leverage

See full
Return on equity-11.6%+0.2pp
Debt / equity0.0×
Current ratio5.2×-1.0×

Where this comes from

Reported directly by OrthoPediatrics in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The official record: OrthoPediatrics’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about OrthoPediatrics's debt - unamortized discount (premium) and issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OrthoPediatrics's debt - unamortized discount (premium) and issuance costs, net?
OrthoPediatrics (KIDS) reported debt - unamortized discount (premium) and issuance costs, net of $4.04M in Q1 2026.
How has OrthoPediatrics's debt - unamortized discount (premium) and issuance costs, net changed year-over-year?
OrthoPediatrics's debt - unamortized discount (premium) and issuance costs, net increased by 17.4% year-over-year, from $3.45M to $4.04M.
What is the long-term trend for OrthoPediatrics's debt - unamortized discount (premium) and issuance costs, net?
Over 2 years (2023 to 2025), OrthoPediatrics's debt - unamortized discount (premium) and issuance costs, net has grown at a 107.7% compound annual growth rate (CAGR), from $1M to $4.33M.
What does debt - unamortized discount (premium) and issuance costs, net mean?
This represents the net adjustment to the face value of debt, accounting for original issue discounts, premiums, and capitalized debt issuance costs. These amounts are amortized over the life of the debt instrument to reflect the effective interest rate. It is essential for reconciling the carrying value of debt to its face value.